



COURT APPROVAL OF CLASS ACTION SETTLEMENT

19 December 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) announces that settlement of the shareholder class action, as previously disclosed on 2 July 2024, has today been approved by the Supreme Court of Victoria.

Under the Court approved terms of settlement, the claims of the plaintiff and group members are dismissed without admission of liability by the Company.

For further information contact:

Dr Tom Duthy
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals to offer patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40 year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.